Prognostic Factors and a Nomogram Predicting Survival in Patients with Breast Ductal Carcinoma in situ with Microinvasion: A Population-Based Study

References

• Lakhani SR. Who Classification of Tumours of the Breast. International Agency for Research on Cancer; 2012.
   Google Scholar
• Edge SB, Byrd DR, Carducci MA, et al. AJCC Cancer Staging Manual. 7th ed; Springer, New York 2010.
   Google Scholar
• Hoda S, Chiu A, Prasad M, et al. Are microinvasion and micrometastasis in breast cancer mountains or molehills? Am J Surg. 2000;180:305–308.11113441
   PubMed Web of Science ®Google Scholar
• Adamovich T, Simmons R. Ductal carcinoma in situ with microinvasion. Am J Surg. 2003;186:112–116.12885600
   PubMed Web of Science ®Google Scholar
• Bianchi S, Vezzosi V. Microinvasive carcinoma of the breast. Pathol Oncol Res. 2008;14:105–111.18493870
   PubMed Web of Science ®Google Scholar
• Shatat L, Gloyeske N, Madan R, et al. Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol. 2013;44:2684–2689.24071019
   PubMed Web of Science ®Google Scholar
• Silver S, Tavassoli F. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998;82:2382–2390.9635531
   PubMed Web of Science ®Google Scholar
• Padmore R, Fowble B, Hoffman J, et al. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience. Cancer. 2000;88:1403–1409.10717623
   PubMed Web of Science ®Google Scholar
• Siegel R, Miller K, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.31912902
   PubMed Web of Science ®Google Scholar
• Pfeiffer R, Webb-Vargas Y, Wheeler W, et al. Proportion of u.S. Trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomark Prev. 2018;27:1214–1222.
   PubMed Web of Science ®Google Scholar
• Gradishar W, Anderson B, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compreh Cancer Net. 2020;18:452–478.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer version 2.2015. J Natl Compreh Cancer Net. 2015;13:448–475.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Gradishar WJ, Anderson BO, et al. NCCN guidelines insights: breast cancer, version 3.2018. J Natl Compreh Cancer Net. 2019;17:118–126.
   PubMed Web of Science ®Google Scholar
• Parikh R, Haffty B, Lannin D, et al. Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys. 2012;82:7–13.20950955
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang S, Wei X, et al. The clinical features and management of women with ductal carcinoma in situ with microinvasion: a retrospective cohort study. Int J Surg. 2015;19:91–94.26013173
   PubMed Web of Science ®Google Scholar
• Wang W, Zhu W, Du F, et al. The demographic features, clinicopathological characteristics and cancer-specific outcomes for patients with microinvasive breast cancer: a seer database analysis. Sci Rep. 2017;7:42045.28165014
   PubMed Web of Science ®Google Scholar
• Champion C, Ren Y, Thomas S, et al. DCIS with microinvasion: is it in situ or invasive disease? Ann Surg Oncol. 2019;26:3124–3132.31342393
   PubMed Web of Science ®Google Scholar
• Sopik V, Sun P, Narod S. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Res Treat. 2018;167:787–795.29119353
   PubMed Web of Science ®Google Scholar
• Plichta JK, Ren Y, Thomas SM, et al. Implications for breast cancer restaging based on the 8th edition AJCC staging manual. Ann Surg. 2020;271:169–176.30312199
   PubMed Web of Science ®Google Scholar
• Lee S, Sohn G, Kim J, et al. A retrospective prognostic evaluation analysis using the 8th edition of the American joint committee on cancer staging system for breast cancer. Breast Cancer Res Treat. 2018;169:257–266.29388016
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173–e180.25846097
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj G, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–1370.18323559
   PubMed Web of Science ®Google Scholar
• Xiong Z, Deng G, Huang X, et al. Score for the survival probability in metastasis breast cancer: a nomogram-based risk assessment model. Cancer Res Treatment. 2018;50:1260–1269.
   Google Scholar
• Lei Z, Li J, Wu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis b virus-related hepatocellular carcinoma within the Milan criteria. JAMA Surg. 2016;151:356–363.26579636
   PubMed Web of Science ®Google Scholar
• Hanley J, McNeil B. The meaning and use of the area under a receiver operating characteristic (roc) curve. Radiology. 1982;143:29–36.7063747
   PubMed Web of Science ®Google Scholar
• Kapoor N, Shamonki J, Sim M, et al. Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer. Ann Surg Oncol. 2013;20:2576–2581.23468047
   PubMed Web of Science ®Google Scholar
• Mamtani A, Nakhlis F, Downs-Canner S, et al. Impact of age on locoregional and distant recurrence after mastectomy for ductal carcinoma in situ with or without microinvasion. Ann Surg Oncol. 2019;26:4264–4271.31440931
   PubMed Web of Science ®Google Scholar
• Si J, Guo R, Pan H, et al. In situ multiple microinvasion foci in ductal carcinoma is associated with an increased risk of recurrence and worse survival outcome. Front Oncol. 2020;10:607502.33344258
   PubMed Web of Science ®Google Scholar
• Jeon Y, You S, Lee J, et al. Optimal treatment of breast cancer in women older than 75 years: a Korea breast cancer registry analysis. Breast Cancer Res Treat. 2019;178:693–701.31493032
   PubMed Web of Science ®Google Scholar
• Bouchardy C, Rapiti E, Blagojevic S, et al. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol. 2007;25:1858–1869.17488984
   PubMed Web of Science ®Google Scholar
• Ring A, Harder H, Langridge C, et al. Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making. Ann Oncol. 2013;24:1211–1219.23334117
   PubMed Web of Science ®Google Scholar
• Bandera E, Qin B, Lin Y, et al. Association of body mass index, central obesity, and body composition with mortality among black breast cancer survivors. JAMA Oncol. 2021. doi:10.1001/jamaoncol.2021.1499
   Web of Science ®Google Scholar
• Foulkes WD, Reis-Filho JS, Narod SA. Tumor size and survival in breast cancer–a reappraisal. Nat Rev Clin Oncol. 2010;7:348–353.20309006
   PubMed Web of Science ®Google Scholar
• Bernards R, Weinberg RA. A progression puzzle. Nature. 2002;418:823.12192390
   PubMed Web of Science ®Google Scholar
• Zheng Y-Z, Wang X-M, Fan L, et al. Breast cancer-specific mortality in small-sized tumor with stage iv breast cancer: a population-based study. Oncologist. 2020;25:1–10.31836614
   PubMed Web of Science ®Google Scholar
• Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312:665–673.3883167
   PubMed Web of Science ®Google Scholar
• Wrubel E, Natwick R, Wright GP. Breast-conserving therapy is associated with improved survival compared with mastectomy for early-stage breast cancer: a propensity score matched comparison using the national cancer database. Ann Surg Oncol. 2021;28:914–919.32661849
   PubMed Web of Science ®Google Scholar
• Niu H, Wei L, Yu J, et al. Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery? Cancer Biol Med. 2016;13:142–149.27144069
   PubMed Web of Science ®Google Scholar
• Liu X-Y, Ma D, Xu X-E, et al. Genomic landscape and endocrine-resistant subgroup in estrogen receptor-positive, progesterone receptor-negative, and her2-negative breast cancer. Theranostics. 2018;8:6386–6399.30613307
   PubMed Web of Science ®Google Scholar
• Li Y, Yang D, Yin X, et al. Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone receptor-positive breast cancer. JAMA Net Open. 2020;3:e1918160.
   Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–1948.21067385
   PubMed Web of Science ®Google Scholar
• Wapnir I, Dignam J, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478–488.21398619
   PubMedGoogle Scholar
• Donker M, Litière S, Werutsky G, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized Phase III trial. J Clin Oncol. 2013;31:4054–4059.24043739
   PubMed Web of Science ®Google Scholar
• Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet (London, England). 2011;378:1707–1716.
   PubMed Web of Science ®Google Scholar